The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are:

1. Whether low-dose oral steroids may lead to a reduction in the recurrence rate among patients with MG.
2. To identify potential biomarkers that can predict disease progression and prognosis.

This study recruits well-controlled patients with MG. Based on patient preferences and considerations such as coexisting conditions (e.g., uncontrolled hypertension, diabetes, severe osteoporosis, obesity), the participants will be non-randomly divided into two groups: a maintenance steroid therapy group and a withdrawal group (withdraw all immunosuppresants). Subsequently, these groups of patients will undergo long-term follow-up assessments.

Inclusion Criteria:

• 1: Attended the outpatient department of neurology of PUMCH from 9/30/2022 to 9/30/2024.
• 2: Diagnosed as myasthenia gravis.
• 3: Follow-up time at PUMCH>6 months.
• 4: The patient understood and signed the informed consent form.

Exclusion Criteria:

• 1: Comorbidities with other conditions that cause skeletal muscle weakness make the clinical symptoms difficult to assess
• 2: Records related to comorbidities and medications were not available at baseline and during follow-up.

Patients with myasthenia gravis who can completed long-term follow-up at PUMCH.